| Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis WJ Jansen, R Ossenkoppele, DL Knol, BM Tijms, P Scheltens, ... Jama 313 (19), 1924-1938, 2015 | 1542 | 2015 |
| Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study SJB Vos, C Xiong, PJ Visser, MS Jasielec, J Hassenstab, EA Grant, ... The Lancet Neurology 12 (10), 957-965, 2013 | 625 | 2013 |
| Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage SJB Vos, F Verhey, L Frölich, J Kornhuber, J Wiltfang, W Maier, O Peters, ... Brain 138 (5), 1327-1338, 2015 | 385 | 2015 |
| Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia RER Slot, SAM Sikkes, J Berkhof, H Brodaty, R Buckley, E Cavedo, ... Alzheimer's & Dementia 15 (3), 465-476, 2019 | 340 | 2019 |
| Suspected non-Alzheimer disease pathophysiology—concept and controversy CR Jack Jr, DS Knopman, G Chételat, D Dickson, AM Fagan, GB Frisoni, ... Nature Reviews Neurology 12 (2), 117-124, 2016 | 288 | 2016 |
| Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World … P Lewczuk, P Riederer, SE O’bryant, MM Verbeek, B Dubois, PJ Visser, ... The world journal of biological psychiatry 19 (4), 244-328, 2018 | 252 | 2018 |
| Association of cerebral amyloid-β aggregation with cognitive functioning in persons without dementia WJ Jansen, R Ossenkoppele, BM Tijms, AM Fagan, O Hansson, ... JAMA psychiatry 75 (1), 84-95, 2018 | 172 | 2018 |
| Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI SJB Vos, IA van Rossum, F Verhey, DL Knol, H Soininen, LO Wahlund, ... Neurology 80 (12), 1124-1132, 2013 | 156 | 2013 |
| Injury markers predict time to dementia in subjects with MCI and amyloid pathology IA van Rossum, SJB Vos, L Burns, DL Knol, P Scheltens, H Soininen, ... Neurology 79 (17), 1809-1816, 2012 | 155 | 2012 |
| Lifestyle for Brain Health (LIBRA): a new model for dementia prevention OJG Schiepers, S Köhler, K Deckers, K Irving, CA O'Donnell, ... International journal of geriatric psychiatry 33 (1), 167-175, 2018 | 144 | 2018 |
| Inflammatory biomarkers in Alzheimer's disease plasma AR Morgan, S Touchard, C Leckey, C O'Hagan, AJ Nevado-Holgado, ... Alzheimer's & dementia 15 (6), 776-787, 2019 | 143 | 2019 |
| Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design IA Van Rossum, S Vos, R Handels, PJ Visser Journal of Alzheimer's Disease 20 (3), 881-891, 2010 | 142 | 2010 |
| Modifiable risk factors for prevention of dementia in midlife, late life and the oldest-old: validation of the LIBRA index SJB Vos, MPJ Van Boxtel, OJG Schiepers, K Deckers, M De Vugt, ... Journal of Alzheimer's Disease 58 (2), 537-547, 2017 | 132 | 2017 |
| Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum WJ Jansen, O Janssen, BM Tijms, SJB Vos, R Ossenkoppele, PJ Visser, ... JAMA neurology 79 (3), 228-243, 2022 | 131 | 2022 |
| Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics BM Tijms, J Gobom, L Reus, I Jansen, S Hong, V Dobricic, F Kilpert, ... Brain 143 (12), 3776-3792, 2020 | 116 | 2020 |
| Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study IS van Maurik, SJ Vos, I Bos, FH Bouwman, CE Teunissen, P Scheltens, ... The Lancet Neurology 18 (11), 1034-1044, 2019 | 115 | 2019 |
| Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum I Bos, S Vos, F Verhey, P Scheltens, C Teunissen, S Engelborghs, ... Alzheimer's & Dementia 15 (5), 644-654, 2019 | 110 | 2019 |
| NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers SJB Vos, BA Gordon, Y Su, PJ Visser, DM Holtzman, JC Morris, ... Neurobiology of aging 44, 1-8, 2016 | 110 | 2016 |
| Variability of CSF Alzheimer’s disease biomarkers: implications for clinical practice SJB Vos, PJ Visser, F Verhey, P Aalten, D Knol, I Ramakers, P Scheltens, ... PloS one 9 (6), e100784, 2014 | 104 | 2014 |
| Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI S Vos, I van Rossum, L Burns, D Knol, P Scheltens, H Soininen, ... Neurobiology of aging 33 (10), 2272-2281, 2012 | 103 | 2012 |
